Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China

Tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR) are becoming the standard treatment option for patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR mutation, but the economic impact of this practice is unclear, especially in a health resource-limited...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Shun, Ye, Ming, Ding, Lieming, Tan, Fenlai, Fu, Jie, Wu, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354787/
https://www.ncbi.nlm.nih.gov/pubmed/28036283
http://dx.doi.org/10.18632/oncotarget.14310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354787/
https://www.ncbi.nlm.nih.gov/pubmed/28036283
http://dx.doi.org/10.18632/oncotarget.14310

Ejemplares similares